Literature DB >> 21786115

Malnutritional neuropathy under intestinal levodopa infusion.

Fabian Klostermann1, Constanze Jugel, Thomas Müller, Frank Marzinzik.   

Abstract

Levodopa/Carbidopa intestinal gel infusion (LCIG) for Parkinson's disease is under debate to provoke polyneuropathy (PNP). In our cohort of 20 thus treated patients, two developed debilitating axonal PNP with deficient pyridoxin and folate levels, and marginal cobalamin. Homocysteine was highly elevated. The neuropathies responded to vitamin replacement. We assume that LCIG can provoke PNP most likely of malnutritional origin. To avoid this side effect, the assessment of predisposing factors before treatment as well as neurophysiological and laboratory screenings appear necessary.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21786115     DOI: 10.1007/s00702-011-0689-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  16 in total

1.  Neuropathy due to hypovitaminosis following excessive weight loss.

Authors:  Philip Heiser; Michael Teepker; J Carsten Möller; Frank M Theisen; Susan Friedel; Johannes Hebebrand; Helmut Remschmidt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-08       Impact factor: 8.829

2.  Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.

Authors:  Davide Manca; Giovanni Cossu; Daniela Murgia; Andrea Molari; Paola Ferrigno; Emanuele Marcia; Maurizio Melis
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

3.  Peripheral neuropathy secondary to isoniazid-induced pyridoxine deficiency.

Authors:  J F Aita; T R Calame
Journal:  Md State Med J       Date:  1972-10

4.  Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

Authors:  Wolfgang H Oertel; Erik Wolters; Cristina Sampaio; Santiago Gimenez-Roldan; Bruno Bergamasco; Max Dujardin; Donald G Grosset; Guy Arnold; Klaus L Leenders; Hans-Peter Hundemer; Alberto Lledó; Andrew Wood; Paul Frewer; Johannes Schwarz
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

5.  Experimental model of pyridoxine (B6) deficiency-induced neuropathy.

Authors:  A L Dellon; E S Dellon; P L Tassler; R D Ellefson; M Hendrickson
Journal:  Ann Plast Surg       Date:  2001-08       Impact factor: 1.539

6.  Challenges in the identification of cobalamin-deficiency polyneuropathy.

Authors:  David S Saperstein; Gil I Wolfe; Gary S Gronseth; Sharon P Nations; Laura L Herbelin; Wilson W Bryan; Richard J Barohn
Journal:  Arch Neurol       Date:  2003-09

7.  Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.

Authors:  Thomas Müller; Kathrin Renger; Wilfried Kuhn
Journal:  Arch Neurol       Date:  2004-05

8.  Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

Authors:  Angelo Antonini; Ioannis U Isaias; Margherita Canesi; Maurizio Zibetti; Francesca Mancini; Luigi Manfredi; Marco Dal Fante; Leonardo Lopiano; Gianni Pezzoli
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

9.  Peripheral neuropathy and severe malnutrition following duodenal switch.

Authors:  Erlend T Aasheim; Dag Hofsø; Jøran Hjelmesaeth; Rune Sandbu
Journal:  Obes Surg       Date:  2008-05-08       Impact factor: 4.129

10.  Neurologic complications of gastric bypass surgery for morbid obesity.

Authors:  Katalin Juhasz-Pocsine; Stacy A Rudnicki; Robert L Archer; Sami I Harik
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

View more
  15 in total

Review 1.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

2.  Intake of vitamin B before onset of Parkinson's disease and atypical parkinsonism and olfactory function at the time of diagnosis.

Authors:  L Håglin; I Johansson; L Forsgren; L Bäckman
Journal:  Eur J Clin Nutr       Date:  2016-10-05       Impact factor: 4.016

3.  Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.

Authors:  Sophie M Lehnerer; Urban M Fietzek; Michael Messner; Andres O Ceballos-Baumann
Journal:  J Neural Transm (Vienna)       Date:  2014-04-08       Impact factor: 3.575

Review 4.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 5.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 6.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep

7.  Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.

Authors:  Sabine Skodda; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2012-07-14       Impact factor: 3.575

8.  Drug therapy in patients with Parkinson's disease.

Authors:  Thomas Müller
Journal:  Transl Neurodegener       Date:  2012-05-24       Impact factor: 8.014

Review 9.  Levodopa-Induced Neuropathy: A Systematic Review.

Authors:  Alberto Romagnolo; Aristide Merola; Carlo Alberto Artusi; Mario Giorgio Rizzone; Maurizio Zibetti; Leonardo Lopiano
Journal:  Mov Disord Clin Pract       Date:  2018-11-08

10.  Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs.

Authors:  Constanze Jugel; Felicitas Ehlen; Birol Taskin; Frank Marzinzik; Thomas Müller; Fabian Klostermann
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.